Related Experiment Videos
Local simvastatin effects on mandibular bone growth and inflammation
David Stein1, Yeonju Lee, Marian J Schmid
1Department of Surgical Specialties, College of Dentistry, University of Nebraska Medical Center, Lincoln, NE 68583-0740, USA.
Journal of Periodontology
|November 9, 2005
Summary
Lowering simvastatin dosage to 0.5 mg promotes bone growth with reduced inflammation. However, cyclooxygenase (COX) inhibition diminishes this bone-regenerative effect, suggesting inflammation is crucial for simvastatin-induced bone growth.
Area of Science:
- Biomaterials Science
- Regenerative Medicine
- Pharmacology
Background:
- Topical simvastatin enhances bone growth but causes significant soft tissue inflammation at high doses (2.2 mg).
- This limits its clinical applicability for bone regeneration.
Purpose of the Study:
- To evaluate the effects of reduced simvastatin doses and cyclooxygenase (COX) inhibitors on bone growth and inflammation.
- To investigate simvastatin's impact on osteogenic gene expression.
Main Methods:
- Rats received varying simvastatin doses (0.1-2.2 mg) or gel vehicle.
- Subsequent studies used 0.5 mg simvastatin with COX inhibitors (NS-398, indomethacin) or no inhibitor.
- Histomorphometry and gene arrays were employed for analysis.
Main Results:
- A 0.5 mg simvastatin dose increased bone area by 45% with reduced swelling compared to 2.2 mg.
- Lower doses (0.1 mg) did not significantly stimulate bone growth.
- COX inhibitors reduced both inflammation and bone growth; simvastatin upregulated key bone-related genes.
Conclusions:
- A 0.5 mg simvastatin dose is effective for bone growth with improved clinical inflammation profile.
- COX-associated inflammation appears essential for simvastatin's in vivo bone regenerative effects.